Mirum Pharmaceuticals Inc (MIRM) has a current Price-to-Book (P/B) ratio of 13.72. Compared to its 3-year average P/B ratio of 8.78, the current P/B ratio is approximately 56.17% higher. Relative to its 5-year average P/B ratio of 7.52, the current P/B ratio is about 82.34% higher. Mirum Pharmaceuticals Inc (MIRM) has a Forward Free Cash Flow (FCF) yield of approximately 1.10%. Compared to its 3-year average FCF yield of -3.47%, the current FCF yield is approximately -131.84% lower. Relative to its 5-year average FCF yield of -10.36%, the current FCF yield is about -110.66% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MIRM competitors is 12.33, providing a benchmark for relative valuation. Mirum Pharmaceuticals Inc Corp (MIRM.O) exhibits a P/S ratio of 6.96, which is -43.59% above the industry average. Given its robust revenue growth of 49.81%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MIRM increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MIRM in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MIRM currently overvalued or undervalued?

What is Mirum Pharmaceuticals Inc (MIRM) fair value?

MIRM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Mirum Pharmaceuticals Inc (MIRM) is between 74.59 to 133.65 according to relative valuation method.

How does MIRM's valuation metrics compare to the industry average?

The average P/S ratio for MIRM's competitors is 12.33, providing a benchmark for relative valuation. Mirum Pharmaceuticals Inc Corp (MIRM) exhibits a P/S ratio of 6.96, which is -43.59% above the industry average. Given its robust revenue growth of 49.81%, this premium appears sustainable.

What is the current P/B ratio for Mirum Pharmaceuticals Inc (MIRM) as of Mar 03 2026?

As of Mar 03 2026, Mirum Pharmaceuticals Inc (MIRM) has a P/B ratio of 13.72. This indicates that the market values MIRM at 13.72 times its book value.

What is the current FCF Yield for Mirum Pharmaceuticals Inc (MIRM) as of Mar 03 2026?

As of Mar 03 2026, Mirum Pharmaceuticals Inc (MIRM) has a FCF Yield of 1.10%. This means that for every dollar of Mirum Pharmaceuticals Inc's market capitalization, the company generates 1.10 cents in free cash flow.

What is the current Forward P/E ratio for Mirum Pharmaceuticals Inc (MIRM) as of Mar 03 2026?

As of Mar 03 2026, Mirum Pharmaceuticals Inc (MIRM) has a Forward P/E ratio of -306.16. This means the market is willing to pay $-306.16 for every dollar of Mirum Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Mirum Pharmaceuticals Inc (MIRM) as of Mar 03 2026?

As of Mar 03 2026, Mirum Pharmaceuticals Inc (MIRM) has a Forward P/S ratio of 6.96. This means the market is valuing MIRM at $6.96 for every dollar of expected revenue over the next 12 months.

MIRM Valuation